FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

Retatrutide

LY3437943 / Reta

Weight Loss & Metabolic

Retatrutide (LY3437943) is a novel triple-hormone receptor agonist developed by Eli Lilly that simultaneously activates GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. In Phase 2 clinical trials, it produced unprecedented weight loss of up to 24.2% of body weight at 48 weeks, surpassing all other incretin-based therapies including semaglutide and tirzepatide. The addition of glucagon receptor agonism to the established GIP/GLP-1 dual agonist framework is hypothesized to provide additive metabolic benefits through increased energy expenditure, enhanced lipid oxidation, and hepatic fat reduction.

作用机制

Triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The glucagon receptor activation increases energy expenditure and hepatic fat oxidation.

研究协议

仅供研究使用,非医疗建议。

Phase 2 research protocols ranged from 1mg to 12mg weekly with dose escalation over 24 weeks.

研究笔记

Clinical Research Status

Retatrutide is in Phase 3 clinical trials (TRIUMPH program) initiated by Eli Lilly in 2023, with multiple trials evaluating efficacy in obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH/NASH). The Phase 2 trial (published in NEJM, June 2023) enrolled 338 adults with obesity and demonstrated dose-dependent weight loss reaching 24.2% at the highest dose (12 mg) over 48 weeks. FDA breakthrough therapy or fast track designation has not been publicly confirmed as of early 2025. Eli Lilly targets potential regulatory submission pending Phase 3 results, with market launch potentially in 2026-2027.

Key Published Findings

The pivotal Phase 2 study published in the New England Journal of Medicine (Jastreboff et al., 2023) showed 24.2% mean body weight reduction at 48 weeks with the 12 mg dose, with 100% of participants in the highest dose group achieving at least 5% weight loss. A companion Phase 2 trial in type 2 diabetes patients (Rosenstock et al., Lancet 2023) demonstrated HbA1c reductions of up to 2.02% alongside significant weight loss. Glucagon receptor agonism contributes an estimated 5-7% additional weight loss through increased resting energy expenditure and hepatic lipid mobilization versus GIP/GLP-1 alone. Liver fat reduction of approximately 82% was observed at the highest dose, suggesting potent MASH/NASH therapeutic potential.

Safety Profile

The most common adverse events in Phase 2 trials were gastrointestinal (nausea, diarrhea, vomiting, constipation), occurring primarily during dose escalation and diminishing over time. GI adverse event rates were comparable to other incretin-based therapies despite the superior weight loss efficacy. Glucagon receptor agonism raised theoretical concerns about hyperglycemia, but glucose levels remained well-controlled in both diabetic and non-diabetic participants. Heart rate increases of 2-4 bpm were observed, consistent with other GLP-1 receptor agonists, and no serious cardiovascular signals emerged. Phase 3 trials will provide larger safety datasets needed for regulatory evaluation.

Drug Interactions & Contraindications

As with other GLP-1 receptor agonists, retatrutide slows gastric emptying and may affect absorption of oral medications requiring precise timing (oral contraceptives, levothyroxine, narrow therapeutic index drugs). Concurrent use with insulin or sulfonylureas carries increased hypoglycemia risk and requires dose reduction of the concomitant agent. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (class effect of GLP-1 agonists based on rodent thyroid C-cell findings). Patients with a history of pancreatitis should use with caution given the GLP-1 class label concern, though causal evidence remains debated.

Comparison to Related Compounds

Retatrutide's 24.2% weight loss at 48 weeks exceeds tirzepatide (22.5% at 72 weeks in SURMOUNT-1) and semaglutide 2.4 mg (15.3% at 68 weeks in STEP-1) in cross-trial comparison, though direct head-to-head data is not yet available. The addition of glucagon receptor agonism provides metabolic benefits absent from tirzepatide (GIP/GLP-1 only) including increased energy expenditure and enhanced hepatic fat clearance. Compared to survodutide (Boehringer's GLP-1/glucagon dual agonist), retatrutide adds GIP agonism which may improve tolerability and provide additional anabolic signaling. If Phase 3 confirms Phase 2 results, retatrutide could represent the most effective pharmacological obesity treatment ever developed.

Community Observations

Retatrutide is not yet commercially available, and community access has been limited to clinical trial participants and gray market research peptide sources of uncertain quality. Early reports from trial participants align with published data describing dramatic weight loss with manageable GI side effects during dose titration. The peptide community closely tracks Eli Lilly's Phase 3 TRIUMPH trial results as a potential successor to tirzepatide (Mounjaro/Zepbound). Given its investigational status, most practitioners recommend tirzepatide or semaglutide as established alternatives until retatrutide receives regulatory approval and quality-controlled manufacturing.

半衰期

~6 days

复溶

Bacteriostatic water (BAC)

存储

冻干

Refrigerate 2-8C. Protect from light.

复溶后

Refrigerate 2-8C. Use within 28 days.

美国法律状态

Research chemical (not FDA-approved)

又称作

LY3437943Reta

常见问题

什么是 Retatrutide?

Retatrutide (LY3437943) is a novel triple-hormone receptor agonist developed by Eli Lilly that simultaneously activates GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. In Phase 2 clinical trials, it produced unprecedented weight loss of up to 24.2% of body weight at 48 weeks, surpassing all other incretin-based therapies including semaglutide and tirzepatide. The addition of glucagon receptor agonism to the established GIP/GLP-1 dual agonist framework is hypothesized to provide additive metabolic benefits through increased energy expenditure, enhanced lipid oxidation, and hepatic fat reduction.

Retatrutide 如何起作用?

Triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The glucagon receptor activation increases energy expenditure and hepatic fat oxidation.

Retatrutide 在美国的监管状态是什么?

Research chemical (not FDA-approved)

Retatrutide 的半衰期是多少?

~6 days

Retatrutide 还有哪些名称?

LY3437943, Reta

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明